Refractory Angina Market to Grow Positively at a Paltry CAGR During the Study Period | Neovasc Inc., BioCardia, and others

DelveInsight's "Refractory Angina - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Refractory Angina market share of the individual therapies, current and forecasted Refractory Angina market size from 2020 to 2034 segmented by seven major markets. The report also offers current Refractory Angina therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Refractory Angina market.
Download sample report @ https://www.delveinsight.com/report-store/refractory-angina-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the Refractory Angina Market Report:
Factors driving the epidemiological growth of Refractory Angina comprises ageing population, prevalence of cardiovascular risk factors, increased awareness and diagnoses, and lifestyle changes. Recognizing these elements is crucial to develop strategies for prevention, early detection, and effective management of refractory angina.
Refractory angina, despite optimal medical, percutaneous, and surgical treatments, remains a debilitating condition often labeled as "no option," posing a significant unmet clinical need. Widespread clinical acceptance and large randomized trials are essential to address crucial issues like mechanism of action, efficacy, logistics, and cost-effectiveness in developing novel treatments for these patients.
Market growth drivers for the Refractory Angina market includes innovation in medical devices, increase in prevalent cases of Coronary artery disease (CAD), and the growing demand for improved quality of life.
The refractory angina market dynamics are expected to change owing to a significant pipeline. Some of the key players involved in the development of novel therapies are Gene Biotherapeutics (Generx), XyloCor Therapeutics (XC001), and others.

Refractory Angina Overview
Refractory angina is a chronic condition characterized by angina due to insufficient blood flow to the heart muscle in cases of coronary artery disease (CAD). Patients with refractory angina experience reproducible, lifestyle-limiting symptoms such as chest pain, shortness of breath, and easy fatigability. These symptoms are often due to totally occluded coronary arteries or diffuse coronary atherosclerosis, making revascularization challenging.

Refractory angina is considered a debilitating disease marked by angina-type pain and persistent cardiac discomfort. The sensation of pressure or pain in the chest results from insufficient blood flow to the heart muscle. This type of angina cannot be managed through a combination of optimal medical therapy, angioplasty, or bypass surgery. It is believed to be caused by reversible myocardial ischemia, which occurs when the heart does not receive enough blood in the presence of CAD.

It is important to recognize that patients diagnosed with refractory angina are a diverse group, and in many cases, functional imaging may not reveal any signs of myocardial ischemia. However, regardless of the underlying cause, patients with persistent chest discomfort often attribute their symptoms to be cardiac in nature and may worry that they could be experiencing a life-threatening cardiac event. Therefore, a clinical suspicion should be based on a convincing clinical history of angina and circumstantial evidence that supports the diagnosis.

The management and treatment of refractory angina are segmented into three categories: pharmacological therapies, non-invasive, and invasive treatments. The core pharmacological-based treatment involves β-blockers, long-acting nitrates, and calcium-channel blockers. These traditional anti-angina agents exert their effects by reducing heart rate, myocardial contractility, and blood pressure, which are important for patients with refractory angina. Non-invasive, non-pharmacological treatments include therapies such as enhanced external counterpulsation (EECP) and transcutaneous electrical nerve stimulation (TENS).

Refractory Angina Epidemiological Insights
As indicated by the analysis, the overall prevalence of angina is 4% in adult's ≥20 years of age, which is approximately 8 million people in the United States.
According to the analysis, the prevalence of angina varied widely across populations, from 0.73% to 14.4% (population-weighted mean 6.7%) in women and from 0.76% to 15.1% (population-weighted mean 5.7%) in men. Prevalence is observed to be strongly correlated within populations between the sexes.
One of the analysis indicated that patients with chronic refractory angina differ from ordinary angina patients in three ways: first, patients with chronic refractory angina pectoris maintain their left ventricular function despite severe three-vessel disease; second, they do not experience severe arrhythmias and therefore their mortality is only about 5%; and third, their angina is debilitating.
The prevalence of no-option disabling refractory angina is much smaller and was estimated to be 35,000 to 50,000 patients.
As per our analysis, it was estimated that around 300,000 to 900,000 patients in the United States have refractory angina, with between 25,000 and 75,000 new cases diagnosed each year.
Based upon the analysis, almost 2.3 million people in the UK are living with some form of coronary artery disease.
As per the analysis, the prevalence of refractory angina pectoris was estimated to be 5% to 10% in stable CAD patients, possibly accounting for 50,000 to 100,000 new cases/year in the United States and 30,000 to 50,000 new cases/year in Europe.

Request a sample report @ https://www.delveinsight.com/report-store/refractory-angina-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Refractory Angina Market Outlook
The current scenario in the Refractory Angina Treatment Market Outlook primarily relies on off-label pharmacological treatments, encompassing a range of medications such as beta-blockers (like Atenolol & Metoprolol), calcium channel blockers (such as Nifedipine), and both long and short-acting nitrates (including Isosorbide Mononitrate & Nitroglycerine). These medications are used to mitigate symptoms and decrease myocardial oxygen demand through mechanisms like vasodilation and heart rate regulation.

Further exploration reveals therapeutic options like nicorandil and ivabradine, which offer alternative strategies for managing stable angina. Nicorandil operates similarly to nitrates by activating potassium channels, while ivabradine provides a distinct approach particularly suited for patients unable to tolerate traditional heart-rate-lowering agents.

Innovative pharmaceuticals like ranolazine introduce a novel mechanism of action. Ranolazine, a piperazine derivative, is believed to exert its anti-anginal effects by inhibiting ischemic-induced late inward Na+ currents, thereby preventing Ca2+ overload and reducing diastolic wall tension and extrinsic coronary artery compression. Additionally, it may enhance endothelial-mediated coronary vasodilatation.

While originally considered primarily as an anti-metabolic drug, ranolazine's therapeutic effects are observed at significantly lower concentrations than those required to inhibit myocardial fatty acid oxidation, demonstrating its potential as a promising avenue in refractory angina management.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the Refractory Angina market in the 7MM is expected to rise significantly during the study period 2020-2034.

Promising Therapies in the Refractory Angina Pipeline
Reducer™ System
CardiAMP Cell Therapy System
And others
Discover more about Refractory Angina therapies in the pipeline @ https://www.delveinsight.com/sample-request/refractory-angina-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Refractory Angina Market
Neovasc Inc.
BioCardia
And others
To understand key companies related to the Refractory Angina Market, get a snapshot of the Refractory Angina Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/refractory-angina-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Refractory Angina Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Refractory Angina Companies: Neovasc Inc., BioCardia, and others
Key Refractory Angina Pipeline Therapies: Reducer™ System, CardiAMP Cell Therapy System, and others
Therapeutic Assessment: Refractory Angina current marketed and emerging therapies
Refractory Angina Market Dynamics: Refractory Angina market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Refractory Angina Market Access and Reimbursement
Table of Contents
1. Refractory Angina Market Key Insights
2. Refractory Angina Market Report Introduction
3. Refractory Angina Market Overview at a Glance
4. Refractory Angina Market Executive Summary
5. Disease Background and Overview
6. Refractory Angina Treatment and Management
7. Refractory Angina Epidemiology and Patient Population
8. Patient Journey
9. Refractory Angina Emerging Drugs
10. 7MM Refractory Angina Market Analysis
11. Refractory Angina Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Refractory Angina Market Drivers
15. Refractory Angina Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports by DelveInsight:

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.